Arrowhead Pharmaceuticals, Inc. (ARWR)
USD 10.87
(-9.91%)
USD 10.87
(-9.91%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 765.55 Million USD | 10.64% |
| 2022 | 691.93 Million USD | -2.56% |
| 2021 | 710.14 Million USD | 35.91% |
| 2020 | 522.5 Million USD | 49.35% |
| 2019 | 349.84 Million USD | 213.45% |
| 2018 | 111.6 Million USD | 7.29% |
| 2017 | 104.02 Million USD | -18.84% |
| 2016 | 128.17 Million USD | -3.09% |
| 2015 | 132.26 Million USD | -27.65% |
| 2014 | 182.81 Million USD | 389.74% |
| 2013 | 37.32 Million USD | 125.86% |
| 2012 | 16.52 Million USD | 4.02% |
| 2011 | 15.88 Million USD | 28.61% |
| 2010 | 12.35 Million USD | 60.4% |
| 2009 | 7.7 Million USD | -55.36% |
| 2008 | 17.25 Million USD | -42.2% |
| 2007 | 29.85 Million USD | -13.53% |
| 2006 | 34.52 Million USD | 18.89% |
| 2005 | 29.04 Million USD | 143.72% |
| 2004 | 11.91 Million USD | 686.03% |
| 2003 | 1.51 Million USD | 2285.01% |
| 2002 | 63.56 Thousand USD | 37.27% |
| 2001 | 46.3 Thousand USD | -28.92% |
| 2000 | 65.14 Thousand USD | -20.83% |
| 1999 | 82.29 Thousand USD | -2.94% |
| 1998 | 84.78 Thousand USD | -21.26% |
| 1997 | 107.67 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 955.15 Million USD | 52.51% |
| 2024 Q1 | 626.28 Million USD | -18.19% |
| 2024 Q3 | 883.75 Million USD | -7.47% |
| 2023 Q2 | 891.3 Million USD | -0.02% |
| 2023 FY | 765.55 Million USD | 10.64% |
| 2023 Q1 | 891.48 Million USD | 28.84% |
| 2023 Q3 | 795.85 Million USD | -10.71% |
| 2023 Q4 | 765.55 Million USD | -3.81% |
| 2022 Q1 | 638.53 Million USD | -10.08% |
| 2022 Q2 | 703.57 Million USD | 10.19% |
| 2022 Q3 | 751.78 Million USD | 6.85% |
| 2022 FY | 691.93 Million USD | -2.56% |
| 2022 Q4 | 691.93 Million USD | -7.96% |
| 2021 Q3 | 734.92 Million USD | -2.89% |
| 2021 Q4 | 710.14 Million USD | -3.37% |
| 2021 FY | 710.14 Million USD | 35.91% |
| 2021 Q1 | 499.25 Million USD | -4.45% |
| 2021 Q2 | 756.79 Million USD | 51.59% |
| 2020 Q2 | 561.07 Million USD | -4.51% |
| 2020 Q3 | 555.72 Million USD | -0.95% |
| 2020 FY | 522.5 Million USD | 49.35% |
| 2020 Q4 | 522.5 Million USD | -5.98% |
| 2020 Q1 | 587.6 Million USD | 67.96% |
| 2019 Q2 | 333.94 Million USD | -2.06% |
| 2019 Q3 | 336.82 Million USD | 0.86% |
| 2019 FY | 349.84 Million USD | 213.45% |
| 2019 Q4 | 349.84 Million USD | 3.86% |
| 2019 Q1 | 340.94 Million USD | 205.48% |
| 2018 Q3 | 112.9 Million USD | -11.1% |
| 2018 Q2 | 126.99 Million USD | 43.96% |
| 2018 Q1 | 88.22 Million USD | -15.19% |
| 2018 FY | 111.6 Million USD | 7.29% |
| 2018 Q4 | 111.6 Million USD | -1.15% |
| 2017 Q2 | 126.87 Million USD | -12.05% |
| 2017 Q4 | 104.02 Million USD | -9.61% |
| 2017 FY | 104.02 Million USD | -18.84% |
| 2017 Q1 | 144.25 Million USD | 12.55% |
| 2017 Q3 | 115.08 Million USD | -9.29% |
| 2016 Q2 | 94.6 Million USD | -15.06% |
| 2016 FY | 128.17 Million USD | -3.09% |
| 2016 Q3 | 85.53 Million USD | -9.59% |
| 2016 Q4 | 128.17 Million USD | 49.86% |
| 2016 Q1 | 111.38 Million USD | -15.79% |
| 2015 FY | 132.26 Million USD | -27.65% |
| 2015 Q1 | 162.13 Million USD | -11.31% |
| 2015 Q2 | 162.37 Million USD | 0.15% |
| 2015 Q3 | 145.19 Million USD | -10.59% |
| 2015 Q4 | 132.26 Million USD | -8.9% |
| 2014 Q3 | 196.62 Million USD | -2.97% |
| 2014 FY | 182.81 Million USD | 389.74% |
| 2014 Q1 | 92.69 Million USD | 148.31% |
| 2014 Q2 | 202.64 Million USD | 118.62% |
| 2014 Q4 | 182.81 Million USD | -7.02% |
| 2013 Q3 | 41.48 Million USD | 234.06% |
| 2013 Q4 | 37.32 Million USD | -10.02% |
| 2013 Q1 | 15.23 Million USD | -7.85% |
| 2013 FY | 37.32 Million USD | 125.86% |
| 2013 Q2 | 12.41 Million USD | -18.46% |
| 2012 Q2 | 20.08 Million USD | -12.93% |
| 2012 FY | 16.52 Million USD | 4.02% |
| 2012 Q1 | 23.06 Million USD | 45.15% |
| 2012 Q3 | 16.48 Million USD | -17.89% |
| 2012 Q4 | 16.52 Million USD | 0.24% |
| 2011 Q4 | 15.88 Million USD | 19.55% |
| 2011 Q1 | 15.18 Million USD | 22.95% |
| 2011 FY | 15.88 Million USD | 28.61% |
| 2011 Q3 | 13.28 Million USD | -12.78% |
| 2011 Q2 | 15.23 Million USD | 0.31% |
| 2010 Q1 | 9.12 Million USD | 18.53% |
| 2010 FY | 12.35 Million USD | 60.4% |
| 2010 Q4 | 12.35 Million USD | -15.36% |
| 2010 Q3 | 14.59 Million USD | 88.14% |
| 2010 Q2 | 7.75 Million USD | -15.02% |
| 2009 Q1 | 15.39 Million USD | -10.81% |
| 2009 Q4 | 7.7 Million USD | -6.06% |
| 2009 Q3 | 8.19 Million USD | -19.37% |
| 2009 FY | 7.7 Million USD | -55.36% |
| 2009 Q2 | 10.16 Million USD | -33.93% |
| 2008 Q4 | 17.25 Million USD | -9.78% |
| 2008 Q2 | 24.82 Million USD | -19.05% |
| 2008 Q3 | 19.12 Million USD | -22.95% |
| 2008 FY | 17.25 Million USD | -42.2% |
| 2008 Q1 | 30.66 Million USD | 2.72% |
| 2007 Q1 | 34.39 Million USD | -0.38% |
| 2007 Q3 | 36.71 Million USD | 36.47% |
| 2007 Q4 | 29.85 Million USD | -18.69% |
| 2007 FY | 29.85 Million USD | -13.53% |
| 2007 Q2 | 26.9 Million USD | -21.78% |
| 2006 Q2 | 45.08 Million USD | 74.21% |
| 2006 Q4 | 34.52 Million USD | -14.92% |
| 2006 FY | 34.52 Million USD | 18.89% |
| 2006 Q1 | 25.88 Million USD | -10.88% |
| 2006 Q3 | 40.58 Million USD | -9.99% |
| 2005 Q4 | 29.04 Million USD | -5.43% |
| 2005 FY | 29.04 Million USD | 143.72% |
| 2005 Q3 | 30.7 Million USD | 110.93% |
| 2005 Q1 | 10.02 Million USD | -15.89% |
| 2005 Q2 | 14.55 Million USD | 45.26% |
| 2004 Q4 | 11.91 Million USD | -1.91% |
| 2004 Q3 | 12.14 Million USD | 5.55% |
| 2004 FY | 11.91 Million USD | 686.03% |
| 2004 Q1 | 2.12 Million USD | 40.35% |
| 2004 Q2 | 11.5 Million USD | 440.92% |
| 2003 FY | 1.51 Million USD | 2285.01% |
| 2003 Q1 | 47.75 Thousand USD | -24.88% |
| 2003 Q2 | 43.28 Thousand USD | -9.36% |
| 2003 Q3 | 46.11 Thousand USD | 6.54% |
| 2003 Q4 | 1.51 Million USD | 3187.44% |
| 2002 Q4 | 63.56 Thousand USD | -39.52% |
| 2002 FY | 63.56 Thousand USD | 37.27% |
| 2002 Q3 | 105.08 Thousand USD | 109.86% |
| 2002 Q2 | 50.07 Thousand USD | 3.02% |
| 2002 Q1 | 48.6 Thousand USD | 4.97% |
| 2001 Q1 | 61.69 Thousand USD | -5.31% |
| 2001 FY | 46.3 Thousand USD | -28.92% |
| 2001 Q3 | 57.98 Thousand USD | -0.52% |
| 2001 Q4 | 46.3 Thousand USD | -20.14% |
| 2001 Q2 | 58.28 Thousand USD | -5.52% |
| 2000 Q4 | 65.14 Thousand USD | -2.25% |
| 2000 Q1 | 70.56 Thousand USD | -29.44% |
| 2000 Q2 | 69.42 Thousand USD | -1.61% |
| 2000 FY | 65.14 Thousand USD | -20.83% |
| 2000 Q3 | 66.65 Thousand USD | -3.99% |
| 1999 FY | 82.29 Thousand USD | -2.94% |
| 1999 Q4 | 100 Thousand USD | 0.0% |
| 1999 Q2 | 100 Thousand USD | 0.0% |
| 1999 Q3 | 100 Thousand USD | 0.0% |
| 1998 Q3 | 100 Thousand USD | 0.0% |
| 1998 Q2 | 100 Thousand USD | 0.0% |
| 1998 FY | 84.78 Thousand USD | -21.26% |
| 1998 Q4 | 100 Thousand USD | 0.0% |
| 1997 FY | 107.67 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 48.555% |
| Alkermes plc | 2.13 Billion USD | 64.163% |
| Agenus Inc. | 313.91 Million USD | -143.874% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 80.011% |
| Aptorum Group Limited | 20.64 Million USD | -3609.053% |
| Ardelyx, Inc. | 297.57 Million USD | -157.26% |
| Bicycle Therapeutics plc | 595.34 Million USD | -28.59% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -938.713% |
| ChromaDex Corporation | 54.96 Million USD | -1292.824% |
| Chimerix, Inc. | 212.77 Million USD | -259.796% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -2607.772% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -73.607% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 65.664% |
| Precision BioSciences, Inc. | 159.78 Million USD | -379.126% |
| Dyadic International, Inc. | 8.21 Million USD | -9214.15% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -2311.947% |
| Fortress Biotech, Inc. | 167.52 Million USD | -356.975% |
| Lantern Pharma Inc. | 43.64 Million USD | -1653.938% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -374.505% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -5177.25% |
| Incyte Corporation | 6.78 Billion USD | 88.712% |
| IO Biotech, Inc. | 150.71 Million USD | -407.937% |
| Jaguar Health, Inc. | 50.76 Million USD | -1408.091% |
| Novavax, Inc. | 1.85 Billion USD | 58.738% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -101.246% |
| Opthea Limited | 188.79 Million USD | -305.502% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 8.104% |
| ContextLogic Inc. | 423 Million USD | -80.982% |
| MiMedx Group, Inc. | 239.04 Million USD | -220.252% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -340.666% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -14708.439% |
| NextCure, Inc. | 129.41 Million USD | -491.534% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -1319.055% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -1984.326% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -2270.057% |
| Vaxcyte, Inc. | 1.4 Billion USD | 45.625% |
| PDS Biotechnology Corporation | 59.39 Million USD | -1189.023% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | -19.515% |
| Pharming Group N.V. | 462.85 Million USD | -65.398% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -1879.193% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -21.796% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -3945.472% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -3945.472% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -363.073% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -1590.445% |
| Acelyrin, Inc. | 742.69 Million USD | -3.078% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -11523.007% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -11856.146% |
| Summit Therapeutics Inc. | 202.94 Million USD | -277.214% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -929.327% |
| Senti Biosciences, Inc. | 119.48 Million USD | -540.715% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -235.266% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -355.214% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -9164.819% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -15936.64% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -63.164% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -519.113% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -178.434% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -61.905% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -7475.972% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -256.891% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -67518.771% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -84.987% |
| Immix Biopharma, Inc. | 19.92 Million USD | -3742.137% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -106.892% |
| MEI Pharma, Inc. | 41.37 Million USD | -1750.277% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -2262.377% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -124.635% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -553.062% |
| Fortress Biotech, Inc. | 167.52 Million USD | -356.975% |
| Precigen, Inc. | 151.04 Million USD | -406.844% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -2150.432% |
| AlloVir, Inc. | 190.79 Million USD | -301.241% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -103.36% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -51.23% |
| ImmuCell Corporation | 43.8 Million USD | -1647.512% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | -17.901% |
| Onconetix, Inc. | 88.82 Million USD | -761.9% |
| PureTech Health plc | 693.97 Million USD | -10.314% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -683.695% |
| Elevation Oncology, Inc. | 89.09 Million USD | -759.292% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -12243.631% |
| Seer, Inc. | 436.26 Million USD | -75.477% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -838.211% |
| Innoviva, Inc. | 1.24 Billion USD | 38.436% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -478.111% |
| ESSA Pharma Inc. | 149.12 Million USD | -413.372% |
| GlycoMimetics, Inc. | 45.31 Million USD | -1589.346% |
| GT Biopharma, Inc. | 14.1 Million USD | -5325.983% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -148.642% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -216.733% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -62.225% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -1410.054% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -704.05% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -121110.663% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -35.175% |
| Aptose Biosciences Inc. | 12.92 Million USD | -5824.159% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -3361.799% |
| Soligenix, Inc. | 9.79 Million USD | -7713.887% |
| Century Therapeutics, Inc. | 360.69 Million USD | -112.246% |
| Kura Oncology, Inc. | 448.93 Million USD | -70.526% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -181.299% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -4326.435% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -590.238% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -273.165% |
| Autolus Therapeutics plc | 375.38 Million USD | -103.94% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -204.23% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -115.537% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -1458.154% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | -15.794% |
| GRI Bio, Inc. | 2.95 Million USD | -25798.241% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -7118.63% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -348.965% |
| IGM Biosciences, Inc. | 423.41 Million USD | -80.806% |
| INmune Bio, Inc. | 57 Million USD | -1243.05% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -244.059% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -812.009% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -2831.256% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -11022.044% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -917.669% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -419.871% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -362.558% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -21.593% |
| Verastem, Inc. | 149.71 Million USD | -411.329% |
| Abeona Therapeutics Inc. | 64 Million USD | -1096.138% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -49.477% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -395.641% |
| Histogen Inc. | 19.07 Million USD | -3913.8% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -3279.895% |
| Surrozen, Inc. | 46.08 Million USD | -1561.354% |
| Organovo Holdings, Inc. | 6.34 Million USD | -11957.836% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -17667.916% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -431.534% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -6386.629% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -917.102% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -8886.143% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -110.914% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -4130.879% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -78.283% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -5970.163% |
| Apollomics, Inc. | 55.38 Million USD | -1282.187% |
| Amarin Corporation plc | 831.68 Million USD | 7.952% |
| Mesoblast Limited | 669.15 Million USD | -14.406% |
| Turnstone Biologics Corp. | 112.81 Million USD | -578.591% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -32.964% |
| Synaptogenix, Inc. | 31.11 Million USD | -2360.501% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -6183.257% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -39.683% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -12936.75% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -10322.538% |
| Exelixis, Inc. | 2.94 Billion USD | 73.982% |
| Better Therapeutics, Inc. | 22.94 Million USD | -3236.756% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -110.006% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 2.939% |
| NLS Pharmaceutics AG | 1.84 Million USD | -41356.461% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -9495.026% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -5109.609% |
| Gritstone bio, Inc. | 177.76 Million USD | -330.644% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -702.634% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -4185.861% |
| Avid Bioservices, Inc. | 336.55 Million USD | -127.466% |
| Insmed Incorporated | 1.32 Billion USD | 42.433% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -7851.024% |
| MediWound Ltd. | 66.45 Million USD | -1051.916% |
| OmniAb, Inc. | 401.98 Million USD | -90.443% |
| Alector, Inc. | 621.82 Million USD | -23.113% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -113.484% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -14134.883% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -1250.37% |
| Zai Lab Limited | 1.03 Billion USD | 26.126% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -60.005% |
| Aura Biosciences, Inc. | 255.07 Million USD | -200.128% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | -2.07% |
| Immunic, Inc. | 54.29 Million USD | -1309.882% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -187.559% |
| Veracyte, Inc. | 1.13 Billion USD | 32.718% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -6375.227% |
| FibroGen, Inc. | 423.52 Million USD | -80.756% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -21691.973% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -16062.462% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -13999.919% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 93.281% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -8594.514% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -47.946% |
| TG Therapeutics, Inc. | 329.58 Million USD | -132.276% |
| Galecto, Inc. | 38.22 Million USD | -1902.647% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -2569.661% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 82.43% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -225.208% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -2981.684% |
| XBiotech Inc. | 227.24 Million USD | -236.887% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -702.634% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -436.853% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -167.754% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -498.7% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -100.407% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 48.656% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -109.831% |
| Vaxxinity, Inc. | 44.35 Million USD | -1626.043% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -48.087% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -4013.807% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -150.96% |
| NexImmune, Inc. | 8.59 Million USD | -8808.035% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -7044.549% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -4369.753% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 97.686% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -3356.04% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -195061.944% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -341.676% |
| Ainos, Inc. | 31.84 Million USD | -2304.236% |
| Pluri Inc. | 39.52 Million USD | -1836.782% |
| Prothena Corporation plc | 696.38 Million USD | -9.933% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -170.881% |
| Celularity Inc. | 143.88 Million USD | -432.043% |
| Rallybio Corporation | 115.62 Million USD | -562.128% |
| Cue Biopharma, Inc. | 61.53 Million USD | -1144.193% |
| MeiraGTx Holdings plc | 458.16 Million USD | -67.09% |
| Omeros Corporation | 378.26 Million USD | -102.383% |
| Humacyte, Inc. | 128.22 Million USD | -497.047% |
| Immunocore Holdings plc | 597 Million USD | -28.233% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -2349.061% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -1017.105% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 27.038% |
| CalciMedica, Inc. | 12.18 Million USD | -6182.741% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -201.814% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -347.932% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -146.13% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -35.424% |
| Pulmatrix, Inc. | 33.95 Million USD | -2154.408% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -2720.128% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -443.492% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 41.156% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -488.031% |
| Cytokinetics, Incorporated | 824.31 Million USD | 7.129% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -3524.258% |
| Nutriband Inc. | 7.51 Million USD | -10084.067% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -869.618% |
| Vor Biopharma Inc. | 209.82 Million USD | -264.847% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 89.4% |
| Evogene Ltd. | 51.1 Million USD | -1398.115% |
| ProKidney Corp. | 420.55 Million USD | -82.035% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -1296.152% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -7941.278% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -40.113% |
| CorMedix Inc. | 82.05 Million USD | -832.918% |
| BioLineRx Ltd. | 63.92 Million USD | -1097.578% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -90.168% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -2614.723% |
| Atai Life Sciences N.V. | 293.47 Million USD | -160.855% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -369.291% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -500.819% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -36.213% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -691.522% |
| MediciNova, Inc. | 66.26 Million USD | -1055.202% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -770.46% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -17055.746% |
| GeoVax Labs, Inc. | 9.28 Million USD | -8146.622% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -30.144% |
| Biomea Fusion, Inc. | 199.92 Million USD | -282.916% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 59.775% |
| Mereo BioPharma Group plc | 66.49 Million USD | -1051.223% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -57.815% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -24.911% |
| Absci Corporation | 234.48 Million USD | -226.489% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -10365.509% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -125.235% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -363.74% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -45.453% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -175.683% |
| Allakos Inc. | 243.61 Million USD | -214.253% |
| Imunon, Inc. | 21.91 Million USD | -3392.789% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -197.078% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -23.175% |
| BioAtla, Inc. | 119.65 Million USD | -539.783% |
| NLS Pharmaceutics AG | 1.84 Million USD | -41356.461% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -23674.907% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | -19.09% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -697.99% |
| XOMA Corporation | 234.3 Million USD | -226.739% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -246.036% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -508.334% |
| aTyr Pharma, Inc. | 122.06 Million USD | -527.157% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -397.425% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -31.93% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -56.1% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -593.002% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -4950.629% |
| Akari Therapeutics, Plc | 4.35 Million USD | -17478.691% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -4393.379% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 55.832% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -24723.459% |
| UroGen Pharma Ltd. | 178.31 Million USD | -329.335% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -62.629% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -137659.823% |
| Orgenesis Inc. | 14.55 Million USD | -5160.803% |
| Entera Bio Ltd. | 11.76 Million USD | -6407.029% |
| GH Research PLC | 226.3 Million USD | -238.291% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -1299.7% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -612.566% |
| Xencor, Inc. | 952.69 Million USD | 19.643% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -9735.233% |
| Replimune Group, Inc. | 487.72 Million USD | -56.965% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -9385.114% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | -18.061% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -24723.459% |
| Portage Biotech Inc. | 7.77 Million USD | -9741.265% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -17055.746% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -176.427% |
| OncoCyte Corporation | 74.89 Million USD | -922.208% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -37551.678% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -13129.639% |
| Purple Biotech Ltd. | 44.3 Million USD | -1628.03% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -2143.31% |
| scPharmaceuticals Inc. | 94.47 Million USD | -710.288% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -4142.47% |
| HilleVax, Inc. | 344.43 Million USD | -122.264% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -24004.282% |
| Tharimmune, Inc. | 10.94 Million USD | -6893.646% |
| Genprex, Inc. | 10.67 Million USD | -7074.41% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -54.285% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -695.362% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -31456.142% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -18278.654% |
| OKYO Pharma Limited | 1.54 Million USD | -49570.4% |
| Savara Inc. | 177.56 Million USD | -331.141% |
| Curis, Inc. | 77.28 Million USD | -890.595% |
| Daré Bioscience, Inc. | 21.28 Million USD | -3497.144% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -1097.133% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -9367.623% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -3852.052% |
| BeiGene, Ltd. | 5.8 Billion USD | 86.813% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -6191.002% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 63.346% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -113.871% |
| Erasca, Inc. | 395.29 Million USD | -93.665% |
| bluebird bio, Inc. | 619.16 Million USD | -23.643% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -17607.302% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 88.81% |
| DBV Technologies S.A. | 182.98 Million USD | -318.366% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -17607.302% |
| Moderna, Inc. | 18.42 Billion USD | 95.845% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -4102.404% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -6507.561% |
| Molecular Templates, Inc. | 35.38 Million USD | -2063.615% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -453.685% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 2.961% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -152.029% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -636.49% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -64.413% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -144.244% |
| MacroGenics, Inc. | 306.82 Million USD | -149.512% |
| RenovoRx, Inc. | 1.46 Million USD | -52120.464% |
| Adicet Bio, Inc. | 207.29 Million USD | -269.306% |
| Prime Medicine, Inc. | 193.85 Million USD | -294.918% |
| Aditxt, Inc. | 44.57 Million USD | -1617.319% |
| Adagene Inc. | 115.72 Million USD | -561.505% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -17087.237% |
| Quantum-Si incorporated | 298.25 Million USD | -156.681% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 48.533% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -9830.468% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -117.932% |
| SciSparc Ltd. | 11.18 Million USD | -6746.289% |
| Vericel Corporation | 353.65 Million USD | -116.467% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -6168.538% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -1245.42% |
| Generation Bio Co. | 374.75 Million USD | -104.279% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -200.61% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -382.794% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -124.262% |
| Invivyd, Inc. | 229.18 Million USD | -234.038% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 9.293% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -6190.846% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -319.734% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -3648.296% |
| 2seventy bio, Inc. | 565.42 Million USD | -35.394% |
| ADMA Biologics, Inc. | 329.18 Million USD | -132.562% |
| Clene Inc. | 52.34 Million USD | -1362.624% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -1203.415% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -489.367% |
| GeoVax Labs, Inc. | 9.28 Million USD | -8146.622% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | -17.111% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -638.87% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -487.143% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -684.763% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -978.288% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -215.623% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 60.943% |
| Evaxion Biotech A/S | 12.88 Million USD | -5839.752% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -203.718% |
| Verve Therapeutics, Inc. | 752.68 Million USD | -1.709% |
| Trevena, Inc. | 40.6 Million USD | -1785.364% |
| Surrozen, Inc. | 46.08 Million USD | -1561.354% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -238.954% |
| Cingulate Inc. | 3.49 Million USD | -21826.565% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -4503.716% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -1065.401% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -6451.788% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -185.104% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | -2.216% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -508.102% |
| Clearmind Medicine Inc. | 4.32 Million USD | -17603.125% |
| Kronos Bio, Inc. | 213.27 Million USD | -258.944% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -379.117% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -8842.727% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -107.754% |
| Statera Biopharma, Inc. | 21.16 Million USD | -3516.265% |
| ImmunityBio, Inc. | 504.45 Million USD | -51.759% |
| Korro Bio, Inc. | 221.66 Million USD | -245.368% |
| Kineta, Inc. | 10.28 Million USD | -7346.28% |
| BioVie Inc. | 25.2 Million USD | -2936.899% |
| Codexis, Inc. | 136.56 Million USD | -460.593% |
| Celularity Inc. | 143.88 Million USD | -432.043% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -20.492% |
| Celcuity Inc. | 191.21 Million USD | -300.353% |
| Virax Biolabs Group Limited | 5.48 Million USD | -13859.816% |
| Cibus, Inc. | 544.41 Million USD | -40.62% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -508.093% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -3626.402% |
| IN8bio, Inc. | 33.7 Million USD | -2171.061% |
| Kodiak Sciences Inc. | 479.37 Million USD | -59.699% |
| Annexon, Inc. | 297.67 Million USD | -157.178% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -342.49% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -456.891% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -3546.701% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 74.397% |
| Eyenovia, Inc. | 28.77 Million USD | -2560.072% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -232.086% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -10497.342% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -1156.528% |
| Arcellx, Inc. | 825.13 Million USD | 7.221% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -837.751% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -65.605% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -2389.6% |
| Moolec Science SA | 24.05 Million USD | -3082.998% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -146.853% |
| Geron Corporation | 394.07 Million USD | -94.265% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -652.681% |
| Royalty Pharma plc | 16.38 Billion USD | 95.327% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -28.671% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -10844.564% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -6265.111% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -238.65% |
| Humacyte, Inc. | 128.22 Million USD | -497.047% |
| Structure Therapeutics Inc. | 482.01 Million USD | -58.823% |
| 89bio, Inc. | 596.26 Million USD | -28.39% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -203.607% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -41281.189% |
| Genelux Corporation | 27.89 Million USD | -2644.603% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -756.293% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -233.677% |
| Notable Labs, Ltd. | 19.54 Million USD | -3817.671% |
| Liquidia Corporation | 120.43 Million USD | -535.677% |
| Mustang Bio, Inc. | 17.74 Million USD | -4214.914% |
| Immunovant, Inc. | 666.71 Million USD | -14.825% |
| Quantum-Si incorporated | 298.25 Million USD | -156.681% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -430.157% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -1313.501% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -336.098% |
| Acasti Pharma Inc. | 73.3 Million USD | -944.409% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -16716.888% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -2831.256% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 20.652% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -14650.753% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -3260.485% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -1383.542% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -323.68% |
| PepGen Inc. | 143.05 Million USD | -435.156% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -1903.171% |
| United Therapeutics Corporation | 7.16 Billion USD | 89.318% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -3890.367% |
| Solid Biosciences Inc. | 164.93 Million USD | -364.143% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -12936.75% |
| Immuneering Corporation | 102.58 Million USD | -646.265% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -17667.916% |
| Silo Pharma, Inc. | 7.74 Million USD | -9783.011% |
| Belite Bio, Inc | 94.64 Million USD | -708.892% |
| XOMA Corporation | 234.3 Million USD | -226.739% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -228.298% |
| Bionomics Limited | 27.64 Million USD | -2668.814% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -90.719% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -612.884% |
| uniQure N.V. | 831.68 Million USD | 7.952% |
| Cassava Sciences, Inc. | 151.66 Million USD | -404.772% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -17087.237% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -179.516% |
| Forte Biosciences, Inc. | 38.98 Million USD | -1863.961% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -18695.251% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -1978.553% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -10497.342% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -21691.973% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -6376.203% |
| Altimmune, Inc. | 210.64 Million USD | -263.441% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 1.585% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -612.884% |
| Compugen Ltd. | 121.33 Million USD | -530.946% |
| Peak Bio, Inc. | 2.59 Million USD | -29384.963% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -344.244% |
| Benitec Biopharma Inc. | 52.21 Million USD | -1366.294% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -123.938% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -2101.57% |
| Zura Bio Limited | 100.84 Million USD | -659.152% |
| PolyPid Ltd. | 15.37 Million USD | -4880.172% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -541.779% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -2101.57% |
| Instil Bio, Inc. | 325.63 Million USD | -135.099% |
| argenx SE | 4.54 Billion USD | 83.147% |
| Immunome, Inc. | 148.54 Million USD | -415.384% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -388.001% |
| Verona Pharma plc | 308.12 Million USD | -148.456% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -780.36% |
| Shattuck Labs, Inc. | 159.56 Million USD | -379.777% |
| CervoMed Inc. | 9.97 Million USD | -7576.615% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -306.223% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -6622.445% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -326.717% |
| Moolec Science SA | 24.05 Million USD | -3082.998% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -12414.173% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -342.658% |
| AnaptysBio, Inc. | 452.38 Million USD | -69.224% |
| Design Therapeutics, Inc. | 289.64 Million USD | -164.309% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -951.221% |
| NeurAxis, Inc. | 509.49 Thousand USD | -150156.134% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -14029.79% |
| Lumos Pharma, Inc. | 40.63 Million USD | -1783.833% |
| Achilles Therapeutics plc | 161.45 Million USD | -374.155% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -780.36% |
| 180 Life Sciences Corp. | 5.25 Million USD | -14455.671% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -987.003% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -8842.727% |
| Nutriband Inc. | 7.51 Million USD | -10084.067% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -200.587% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -284.118% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -904.503% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -1221.832% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -45.393% |
| Palisade Bio, Inc. | 14.05 Million USD | -5347.993% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -264.037% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 47.555% |
| Neurogene Inc. | 222.57 Million USD | -243.955% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | -18.393% |
| AEON Biopharma, Inc. | 6.84 Million USD | -11084.105% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -68.983% |
| Sesen Bio, Inc. | 189.17 Million USD | -304.681% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -181.591% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -5483.133% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 1.896% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -186.73% |
| Athira Pharma, Inc. | 160.24 Million USD | -377.738% |
| Vaccinex, Inc. | 3.63 Million USD | -20983.779% |
| HCW Biologics Inc. | 28.51 Million USD | -2584.861% |
| XOMA Corporation | 234.3 Million USD | -226.739% |
| Nektar Therapeutics | 398.03 Million USD | -92.334% |
| Arvinas, Inc. | 1.3 Billion USD | 41.319% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -4393.379% |
| Merus N.V. | 458.49 Million USD | -66.971% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -274.599% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -324.825% |
| Rezolute, Inc. | 132.73 Million USD | -476.743% |
| Clene Inc. | 52.34 Million USD | -1362.624% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -5029.712% |
| BeyondSpring Inc. | 24.8 Million USD | -2985.908% |
| Synlogic, Inc. | 75.55 Million USD | -913.305% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -6353.819% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -8075.481% |
| Peak Bio, Inc. | 2.59 Million USD | -29384.963% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -337.876% |
| Krystal Biotech, Inc. | 818.35 Million USD | 6.452% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -218.399% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | -5.479% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -21301.028% |
| MannKind Corporation | 475.19 Million USD | -61.102% |
| Ikena Oncology, Inc. | 192.09 Million USD | -298.534% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -5624.181% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -556.906% |
| Gossamer Bio, Inc. | 311.91 Million USD | -145.435% |
| CohBar, Inc. | 16.36 Million USD | -4577.793% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -2077.152% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -10365.509% |
| Legend Biotech Corporation | 1.84 Billion USD | 58.588% |
| Mural Oncology plc | 301.74 Million USD | -153.708% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -2352.513% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -13377.067% |
| Disc Medicine, Inc. | 367.99 Million USD | -108.033% |
| Champions Oncology, Inc. | 26.13 Million USD | -2829.558% |
| REGENXBIO Inc. | 573.97 Million USD | -33.378% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -28169.127% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -395.869% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -6239.671% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -125.139% |
| Vaxart, Inc. | 91.83 Million USD | -733.662% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -1177.967% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -416.125% |
| Cellectis S.A. | 334.27 Million USD | -129.022% |
| Longeveron Inc. | 12.17 Million USD | -6186.352% |
| Repare Therapeutics Inc. | 253.9 Million USD | -201.516% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 76.55% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -281.162% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 63.346% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -47010.892% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -175.665% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -369.382% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -451.773% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -2899.577% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 96.632% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 33.656% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -6168.538% |
| Veru Inc. | 50.59 Million USD | -1413.07% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -1580.574% |
| Cingulate Inc. | 3.49 Million USD | -21826.565% |
| Passage Bio, Inc. | 150.54 Million USD | -408.52% |
| Context Therapeutics Inc. | 16.06 Million USD | -4666.013% |
| Exicure, Inc. | 11.58 Million USD | -6510.984% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -103.578% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -373.61% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -4281.593% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -130.072% |
| Nuvalent, Inc. | 732.38 Million USD | -4.529% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -5022.778% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -754.85% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -5294.63% |
| OmniAb, Inc. | 401.98 Million USD | -90.443% |
| Anew Medical, Inc. | 19.45 Million USD | -3834.796% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -2764.387% |
| Lipocine Inc. | 23 Million USD | -3228.332% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -447.578% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -150.537% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -812.009% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -529.877% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -9547.788% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 13.23% |
| Ocugen, Inc. | 64.54 Million USD | -1086.038% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -514.699% |
| Q32 Bio Inc. | 306.11 Million USD | -150.083% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -18092.776% |
| Alumis Inc. Common Stock | 89.61 Million USD | -754.296% |
| Equillium, Inc. | 50.53 Million USD | -1415.045% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -918.089% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -1754.826% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -44909.886% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -2828.549% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -1087.989% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -20440.08% |
| Dominari Holdings Inc. | 57.55 Million USD | -1230.053% |
| Edesa Biotech, Inc. | 8.89 Million USD | -8510.96% |
| vTv Therapeutics Inc. | 11.01 Million USD | -6848.194% |
| Bio-Techne Corporation | 2.81 Billion USD | 72.787% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 18.308% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 5.656% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -175.711% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -1735.768% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | -14.674% |
| Nkarta, Inc. | 378.88 Million USD | -102.054% |
| BioCardia, Inc. | 2.98 Million USD | -25529.461% |
| Iterum Therapeutics plc | 26.25 Million USD | -2815.389% |